Renaissance Technologies (RenTech)'s MAZE Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 27,100 shares of Maze Therapeutics, Inc. (MAZE) worth $1.12 M, representing 0.00% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Renaissance Technologies (RenTech) has initiated a new position in MAZE, representing a fresh investment thesis on this company. Largest reduction occurred in Q4 2025, reducing 59,000 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Maze Therapeutics (MAZE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Maze Therapeutics (MAZE) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -59,000 | Reduce 68.52% | 27,100 | $41.43 |
| Q3 2025 | +86,100 | New Buy | 86,100 | $25.93 |
Renaissance Technologies (RenTech)'s Maze Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Maze Therapeutics, Inc. (MAZE) in Q3 2025, acquiring 86,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Maze Therapeutics, Inc. (MAZE) for 2 quarters since Q3 2025.
Renaissance Technologies (RenTech)'s largest addition to Maze Therapeutics, Inc. (MAZE) was in Q3 2025, adding 86,100 shares worth $2.23 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 27,100 shares of Maze Therapeutics, Inc. (MAZE), valued at approximately $1.12 M.
As of the Q4 2025 filing, Maze Therapeutics, Inc. (MAZE) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Maze Therapeutics, Inc. (MAZE) was 86,100 shares, as reported at the end of Q3 2025.